
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx Corp reported a total revenue of $83.8 million for the full year 2024, marking a 22% increase from the previous year, with notably strong performance stemming from both domestic and international sales. The company's quarterly revenue in Q4 2024 reached a record $23.8 million, reflecting a 23% growth year-over-year, indicating robust demand for its innovative medical solutions. Additionally, the expansion of reimbursement coverage and advancements in patient selection technology are projected to enhance adoption rates and market penetration, further solidifying Pulmonx's positive growth outlook in the medical device sector.
Bears say
Pulmonx Corp reported a gross profit of $17.6 million for the quarter, reflecting a slight decrease in gross margin to 74%, indicating potential pressures on profitability. The company's cash reserves decreased to $101.5 million, suggesting a potential concern over liquidity as expenses rise and cash flow stability is questioned. Additionally, the company's exposure to the small capital market increases volatility and risk, which could deter potential investors amid the broader market challenges posed by the healthcare industry's evolving dynamics and unmet medical needs.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares